Acemannan ameliorates STZ-activated diabetes by attenuating high glucose via inhibiting inflammatory cytokines and apoptosis pathway

Int J Biol Macromol. 2023 Dec 31;253(Pt 5):127127. doi: 10.1016/j.ijbiomac.2023.127127. Epub 2023 Sep 28.

Abstract

Acemannan, the main polysaccharide in Aloe vera, is a -(1, 4)-acetylated polymannose. According to numerous research findings, acemannan is a viable alternative for the treatment of pathological disorders. Streptozotocin (STZ, 60 mg/kg) administered intraperitoneally caused type 2 diabetes in rats. The current study sought to determine the anti-diabetic efficacy of acemannan (25 and 50 mg/kg) in STZ-injected rats. Different biochemical parameters including HbA1C, glucose and serum insulin, lipid profile, inflammatory markers, antioxidant, oxidative balance, liver function test, glycogen and creatinine, and caspase-3 were evaluated. In addition, a molecular docking study was performed to estimate acemannan's binding affinity to inflammatory markers. Acemannan may be a potent anti-diabetic agent for the treatment of diabetic patients, which will aid in future research into alternative diabetes medications.

Keywords: Acemannan; Apoptosis; Docking study; Polysaccharide; Streptozotocin.

MeSH terms

  • Animals
  • Apoptosis
  • Cytokines*
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucose
  • Humans
  • Molecular Docking Simulation
  • Oxidative Stress
  • Rats
  • Streptozocin

Substances

  • acemannan
  • Cytokines
  • Streptozocin
  • Glucose